Group 1: Financial Performance - Standard BioTools reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $41.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $37.21 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $40.7 million, and for the current fiscal year, it is -$0.14 on revenues of $169.3 million [7] Group 2: Market Performance - Standard BioTools shares have declined approximately 25.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company has surpassed consensus revenue estimates three times over the last four quarters, but has only exceeded consensus EPS estimates once in the same period [2][1] Group 3: Industry Outlook - The Medical Info Systems industry, to which Standard BioTools belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

[Overview and Strategic Highlights](index=1&type=section&id=Standard%20BioTools%20Reports%20Second%20Quarter%202025%20Financial%20Results) [Recent Highlights and CEO Commentary](index=1&type=section&id=Recent%20Highlights) The company announced the strategic sale of SomaLogic to Illumina, strengthening its balance sheet to pursue inorganic growth and a 2026 profitability target - Announced the strategic sale of SomaLogic to Illumina for up to **$425 million** in total cash consideration, plus potential future royalties[5](index=5&type=chunk) - The company expects to have at least **$550 million in cash** and cash equivalents upon closing the Illumina transaction, which will be used to fuel its inorganic growth strategy[3](index=3&type=chunk)[5](index=5&type=chunk) - Management is driving toward a profitability target, aiming for **adjusted EBITDA break-even in 2026**[3](index=3&type=chunk)[5](index=5&type=chunk) - CEO Michael Egholm stated the company is positioned to **"continue playing offense"** by strategically deploying capital into high-quality, underappreciated assets to drive scale and growth[3](index=3&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) [Financial Highlights (Continuing Operations)](index=1&type=section&id=Financial%20Results%20Table%3A%20Continuing%20Operations) Q2 2025 continuing operations revenue was $21.8 million, with improved non-GAAP gross margin and a narrower operating loss Q2 & H1 2025 Financial Summary (Continuing Operations) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $21.8M | $22.5M | $42.0M | $44.1M | | Gross Margin | 48.8% | 46.1% | 51.6% | 48.5% | | Non-GAAP Gross Margin | 54.1% | 48.6% | 55.6% | 54.1% | | Operating Loss | $(25.7)M | $(30.3)M | $(52.7)M | $(74.7)M | | Net Loss from Continuing Operations | $(17.7)M | $(25.4)M | $(41.0)M | $(41.8)M | | Adjusted EBITDA | $(16.1)M | $(17.4)M | $(30.2)M | $(34.3)M | | Cash, Cash Equivalents, & Short-term Investments | $239.7M | $397.2M | $239.7M | $397.2M | [Detailed Financial Results (Continuing Operations)](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results%3A%20Continuing%20Operations) Q2 2025 revenue from continuing operations decreased 3% to $21.8 million, driven by lower instrument sales, though margins and net loss improved Q2 2025 Revenue Breakdown (Continuing Operations) | Revenue Stream | Q2 2025 | YoY Change | | :--- | :--- | :--- | | Consumables | $10.5M | +18% | | Instruments | $5.2M | -26% | | Services | $6.1M | -8% | | **Total Revenue** | **$21.8M** | **-3%** | - Gross margins improved to **48.8% (54.1% non-GAAP)** in Q2 2025 from 46.1% (48.6% non-GAAP) in Q2 2024, driven by favorable product mix and improvements from the Standard BioTools Business System (SBS)[9](index=9&type=chunk) - Operating expenses **decreased by 11% YoY** to $36.3 million, attributed to the realization of merger cost synergies and continued productivity gains[9](index=9&type=chunk) - Net loss from continuing operations **improved by 31%** to $17.7 million in Q2 2025, compared to a net loss of $25.4 million in Q2 2024[9](index=9&type=chunk) [Full Year 2025 Revenue Outlook](index=2&type=section&id=Full%20Year%202025%20Revenue%20Outlook) The company forecasts full-year 2025 combined revenue of $165-$175 million and continuing operations revenue of $78-$83 million Fiscal Year 2025 Revenue Guidance | Revenue Category | FY 2025 Outlook | | :--- | :--- | | Combined Revenue | $165M - $175M | | Revenue from Continuing Operations | $78M - $83M | - The outlook assumes a high single-digit millions decline in Americas academic revenue due to anticipated NIH funding pressures, with a more pronounced impact on continuing operations[7](index=7&type=chunk) [Discontinued Operations Performance (SomaLogic)](index=12&type=section&id=Condensed%20Results%20of%20Operations%20Discontinued%20Operations) The discontinued SomaLogic business generated $20.2 million in revenue for Q2 2025, with its operating loss narrowing to $15.8 million Discontinued Operations Financial Summary | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $20.2M | $14.7M | $40.8M | $38.6M | | Loss from Discontinued Operations | $(15.8)M | $(20.3)M | $(18.4)M | $(36.0)M | [Combined Company Performance](index=16&type=section&id=Condensed%20Combined%20Results%20of%20Operations) On a combined basis, total Q2 2025 revenue grew to $42.0 million, and the total net loss improved to $33.5 million Combined Company Financial Summary | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $42.0M | $37.2M | $82.8M | $82.7M | | Net Loss | $(33.5)M | $(45.7)M | $(59.5)M | $(77.9)M | [Financial Statements](index=5&type=section&id=Financial%20Statements) [Consolidated Statements of Operations (Continuing Operations)](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Continuing operations generated $21.8 million in Q2 2025 revenue, resulting in a net loss of $17.7 million, or ($0.05) per share Q2 2025 Statement of Operations Highlights (Continuing) | Line Item | Q2 2025 (in thousands) | Q2 2024 (in thousands) | | :--- | :--- | :--- | | Total revenue | $21,762 | $22,492 | | Gross profit | $10,628 | $10,374 | | Total operating expenses | $36,325 | $40,635 | | Loss from continuing operations | $(25,697) | $(30,261) | | Net loss from continuing operations | $(17,673) | $(25,444) | | Net loss per share from continuing operations | $(0.05) | $(0.07) | [Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, the company held total assets of $557.0 million, including $158.6 million in cash and cash equivalents Balance Sheet Highlights (as of June 30, 2025) | Account | Amount (in thousands) | | :--- | :--- | | **Assets** | | | Cash and cash equivalents | $158,617 | | Short-term investments | $78,468 | | Current assets held for sale | $223,089 | | **Total Assets** | **$556,965** | | **Liabilities & Equity** | | | Total current liabilities | $98,024 | | **Total Liabilities** | **$132,430** | | **Total Stockholders' Equity** | **$424,535** | [Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) For the first half of 2025, net cash used in operating activities was $51.0 million, resulting in a period-end cash balance of $161.2 million Cash Flow Summary (Six Months Ended June 30, 2025) | Activity | Amount (in thousands) | | :--- | :--- | | Net cash used in operating activities | $(50,951) | | Net cash provided by investing activities | $42,130 | | Net cash provided by financing activities | $62 | | **Net decrease in cash** | **$(7,614)** | | **Cash at end of period** | **$161,204** | [Non-GAAP Reconciliations](index=9&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20FINANCIAL%20INFORMATION) [Continuing Operations Reconciliations](index=9&type=section&id=Continuing%20Operations%20Reconciliations) For Q2 2025, adjusted EBITDA for continuing operations was a loss of $16.1 million, an improvement from a $17.4 million loss in the prior year Q2 2025 Non-GAAP Reconciliation Highlights (Continuing) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $10.6M | $11.8M | | Gross Margin | 48.8% | 54.1% | | Operating Expenses | $36.3M | $27.9M | | Adjusted EBITDA | N/A | $(16.1)M | [Discontinued Operations Reconciliations](index=13&type=section&id=Discontinued%20Operations%20Reconciliations) The discontinued SomaLogic operations showed an adjusted EBITDA loss of $2.4 million in Q2 2025, a substantial improvement from a $13.7 million loss in Q2 2024 Q2 2025 Non-GAAP Reconciliation Highlights (Discontinued) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $8.6M | $10.4M | | Gross Margin | 42.8% | 51.3% | | Operating Expenses | $24.8M | $12.8M | | Adjusted EBITDA | N/A | $(2.4)M | [Combined Company Reconciliations](index=17&type=section&id=Combined%20Company%20Reconciliations) The combined adjusted EBITDA loss for Q2 2025 was $18.6 million, a marked improvement from a $31.0 million loss in the prior-year quarter Q2 2025 Non-GAAP Reconciliation Highlights (Combined) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $19.3M | $22.1M | | Gross Margin | 45.9% | 52.8% | | Operating Expenses | $61.1M | $40.7M | | Adjusted EBITDA | N/A | $(18.6)M | [Company Information and Disclosures](index=3&type=section&id=Company%20Information%20and%20Disclosures) [Use of Non-GAAP Measures and Forward-Looking Statements](index=3&type=section&id=Use%20of%20Non-GAAP%20Financial%20Information) The company utilizes non-GAAP measures to show core performance and cautions that forward-looking statements are subject to risks and uncertainties - Management uses non-GAAP financial measures to supplement GAAP results, believing they provide useful information by excluding items not indicative of core operating performance[12](index=12&type=chunk) - Forward-looking statements involve risks related to divestitures, acquisitions, integration, cost savings, market conditions, NIH funding pressures, and competition[13](index=13&type=chunk)[14](index=14&type=chunk) [About Standard BioTools Inc.](index=4&type=section&id=About%20Standard%20BioTools%20Inc.) Standard BioTools provides essential technologies like SomaScan and mass cytometry to biomedical researchers, focusing on oncology and immunology - The company's core technologies include SomaScan, mass cytometry, and microfluidics[15](index=15&type=chunk) - Standard BioTools serves a global client base in academic, government, and private research sectors, with a focus on oncology and immunology[15](index=15&type=chunk)

Core Viewpoint - Standard BioTools Inc. reported its second quarter 2025 financial results, highlighting a strategic sale of SomaLogic to Illumina, which is expected to unlock up to $425 million in cash and enhance the company's financial position towards profitability by 2026 [3][6][10]. Financial Performance - Revenue for the second quarter of 2025 was $21.8 million, a decrease of 3% year-over-year, while total revenue for the first half of 2025 was $42 million, down 5% year-over-year [4][7]. - Consumables revenue increased by 18% year-over-year to $10.5 million in the second quarter, although total consumables revenue for the first half decreased by 3% to $18.6 million [7][21]. - Instruments revenue fell by 26% year-over-year to $5.2 million in the second quarter, with a slight decrease of 1% to $11.9 million for the first half [13][21]. - Services revenue was $6.1 million in the second quarter, down 8% year-over-year, and $11.5 million for the first half, down 11% year-over-year [13][21]. Gross Margin and Operating Expenses - Gross margin for the second quarter of 2025 was approximately 48.8%, compared to 46.1% in the same quarter of 2024, while non-GAAP gross margin was 54.1%, up from 48.6% [13][22]. - Operating expenses decreased by 11% year-over-year to $36.3 million in the second quarter, with non-GAAP operating expenses down by 1% to $27.9 million [13][23]. - The company achieved a net loss of $17.7 million in the second quarter, an improvement of 31% compared to a net loss of $25.4 million in the same quarter of 2024 [13][25]. Cash Position and Future Outlook - As of June 30, 2025, the company had $239.7 million in cash and cash equivalents, with expectations to reach at least $550 million upon closing the transaction with Illumina [6][19]. - The company is targeting adjusted EBITDA break-even in 2026, supported by a strong balance sheet and a lean operating model [3][6]. Strategic Developments - The sale of SomaLogic is seen as a pivotal milestone for the company, allowing for strategic capital deployment into high-quality assets to drive growth and long-term shareholder value [3][6]. - The company anticipates a high single-digit million decline in Americas academic revenue due to NIH funding pressures, impacting continuing operations more significantly [9]. Revenue Outlook - For fiscal year 2025, the company expects combined revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [8].

Core Insights - Standard BioTools Inc. announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to analyze 100,000 plasma samples, highlighting its strategic position in the biobank segment and its role in global health initiatives [1][2] Company Overview - Standard BioTools is a leader in population proteomics, with the SomaScan platform being utilized in over 30 biobank studies globally, including three major studies this year totaling nearly 160,000 samples [4] - The company provides essential next-generation technologies that assist biomedical researchers in developing better medicines faster, focusing on oncology, immunology, and immunotherapy [7] Industry Context - The PRECISE-SG100K initiative aims to transform healthcare in Singapore by leveraging data-driven solutions to improve patient outcomes, drawing on a multi-ethnic population and extensive health insights [3][10] - Population proteomics studies are generating new datasets that enhance understanding of protein expression dynamics, revealing insights into gene-to-protein correlations and new therapeutic targets [6]

Company Announcement - Standard BioTools Inc. will report its second quarter 2025 financial results on August 11, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and operational progress [1] Access Information - Individuals can access the conference call by dialing US domestic callers: (888) 346-3970 and outside US callers: (412) 902-4297 [1] - Live audio of the webcast will be available on the Investor Relations page of the company's website and will be archived for later access [2] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [3] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease, focusing on oncology, immunology, and immunotherapy [3] - Standard BioTools collaborates with various entities including academic, government, pharmaceutical, and clinical laboratories globally [3]

Company Overview - Labrador Gold Corp. is a Canadian mineral exploration company focused on acquiring and exploring gold projects in Eastern Canada [4] - The company currently has approximately CAD $18.1 million in cash [4] - Labrador Gold has 170,009,979 common shares issued and outstanding, trading on the TSX Venture Exchange under the symbol LAB [7] Leadership Appointment - Ryan Weston has been appointed as Vice President Exploration, bringing over 20 years of global experience in base and precious metals exploration [2] - Weston previously played key roles in the successful sales of Carlisle Goldfields for CAD $28 million in 2016 and Noront Resources for CAD $686 million in 2022 [2] - He has served as Vice President Exploration at Wyloo, leading initiatives in Ontario's Ring of Fire region [2] Strategic Vision - Weston expressed confidence in Labrador Gold's strong position to pursue major gold discoveries without the immediate need for additional financing [3] - The company aims to leverage Weston's extensive experience in leading technical teams for new gold projects [3] Exploration Projects - The Hopedale property covers a significant portion of the Florence Lake greenstone belt, which is underexplored compared to similar global belts [5] - Labrador Gold has identified gold anomalies over a 3-kilometer section of the northern part of the Florence Lake greenstone belt, with five gold occurrences discovered [5] - The Borden Lake project near Chapleau, Ontario, has shown promising results with up to 48 gold grains identified in till samples [6]

Core Viewpoint - Standard BioTools Inc. announced the strategic sale of SomaLogic to Illumina for a total of up to $425 million, which includes an upfront payment of $350 million and potential milestone payments of up to $75 million, simplifying its operating structure and enabling adjusted EBITDA break-even [1][2][5]. Financial Details - The transaction includes an upfront cash payment of $350 million at closing and up to $75 million in near-term milestone payments based on specified revenue targets for fiscal years 2025 and 2026 [5][6]. - Standard BioTools will retain a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for 10 years post-transaction [6]. Strategic Implications - The sale is expected to provide Standard BioTools with at least $550 million in cash at closing, allowing for future inorganic growth strategies and long-term value creation [1][2]. - The transaction is part of a disciplined M&A strategy aimed at acquiring high-potential assets with validated science and a clear commercialization path [3][4]. Operational Impact - The sale significantly simplifies the operational and organizational structure of Standard BioTools, facilitating a path to achieve adjusted EBITDA break-even, which is a key priority for the company [2][4]. - The management team believes that disciplined operations and focused execution can unlock meaningful value in the life sciences sector [2]. Regulatory and Advisory Aspects - The transaction is subject to regulatory approvals and is expected to close in the first half of 2026 [7]. - Centerview Partners LLC is serving as the financial advisor to Standard BioTools, with additional legal counsel from Freshfields LLP and Richards, Layton & Finger, P.A. [8].

Core Viewpoint - Labrador Gold Corp. has initiated its 2025 exploration program at the Hopedale gold project in Labrador, focusing on the underexplored Florence Lake greenstone belt, which spans 43 km [1][13]. Exploration Focus - The exploration will concentrate on the Thurber Gold trend, a 3 km area with significant gold occurrences, defined by four notable gold sites and anomalous gold in surrounding rock and soil samples [2][5]. - Historical sampling has shown promising results, with values up to 32.3 g/t Au at Thurber North and channel sampling at TD500 returning values of up to 14.0 g/t Au over 0.61 m [3][4]. Survey and Mapping - A 33-line kilometre IP/Resistivity survey will be conducted to identify chargeability anomalies linked to gold mineralization, alongside detailed mapping and prospecting in the grid area [4][5]. - Systematic rock and soil sampling has identified 52 samples over 0.5 g/t Au, with 33 samples exceeding 1 g/t Au, aiming to define drill targets along the Thurber Gold trend [5]. Additional Discoveries - Recent discoveries in the Rusty Ridge area include gold at the Fire Ant occurrence and copper-silver at the Stone Fly occurrence, with initial sampling at Fire Ant returning values up to 106 g/t Au [5][6]. - Follow-up sampling in 2024 at Fire Ant yielded values of 9.35 g/t Au and 0.19 g/t Au with 10.8 g/t Ag [6]. Growth Strategy - Labrador Gold is actively pursuing additional gold projects with resource potential, having reviewed over 40 projects, focusing on Canadian opportunities based on geological potential and jurisdictional stability [6]. Financial Position - The company has approximately $18.1 million in cash, supporting its exploration and acquisition strategies [12].

Core Insights - Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series to discuss advancements in the field of proteomics and its implications for healthcare [1] - The first session will focus on high-plex, high-quality proteomics, featuring insights from researchers involved in the EPIC cancer study [2] - Future sessions will cover various topics, including comparative metrics for proteomic platforms, deployment in biobanks, and the role of proteomics in accelerating drug development [3][4][5] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies aimed at enhancing biomedical research and drug development [7] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide reliable insights into health and disease [7] - Standard BioTools collaborates with academic, government, and clinical laboratories globally, focusing on critical areas in translational and clinical research [9]

Company Overview - Labrador Gold Corp. is a Canadian mineral exploration company focused on acquiring and exploring gold projects in Eastern Canada [2] - The company currently has approximately $18.1 million in cash [2] - Labrador Gold has 170,009,979 common shares issued and outstanding, trading on the TSX Venture Exchange under the symbol LAB [5] Recent Developments - Kai Hoffmann has resigned as a director of the company, having been part of the Board of Directors since 2019 [1] - The company's President and CEO, Roger Moss, expressed gratitude for Hoffmann's contributions over the past six years [2] Exploration Projects - The Hopedale property covers much of the Florence Lake greenstone belt, which is 60 km long and has shown gold anomalies over a 3 km section [3] - Five gold occurrences have been identified along the trend, with four discovered by Labrador Gold [3] - Anomalous gold has also been found over approximately 40 km along the southern section of the greenstone belt, with potential for critical metals such as copper, nickel, and cobalt [3] Borden Lake Project - The Borden Lake project is located near Chapleau, Ontario, southeast of Newmont Corporation's Borden gold mine [4] - Past exploration identified two anomalous zones based on geochemistry and geophysics, with up to 48 gold grains found in till samples [4]